Matthew G. Johnson

3.3k total citations
36 papers, 960 citations indexed

About

Matthew G. Johnson is a scholar working on Epidemiology, Pharmacology and Infectious Diseases. According to data from OpenAlex, Matthew G. Johnson has authored 36 papers receiving a total of 960 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Epidemiology, 13 papers in Pharmacology and 10 papers in Infectious Diseases. Recurrent topics in Matthew G. Johnson's work include Antibiotics Pharmacokinetics and Efficacy (12 papers), Antibiotic Resistance in Bacteria (10 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). Matthew G. Johnson is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (12 papers), Antibiotic Resistance in Bacteria (10 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). Matthew G. Johnson collaborates with scholars based in United States, Greece and France. Matthew G. Johnson's co-authors include Jason E. Stout, M. Molly McMahon, Hartzell V. Schaff, Martin Abel, Charles J. Mullany, Peter C. O’Brien, Arthur Robin Williams, Susanne M. Cutshall, Gregory A. Nuttall and Gunjan Y. Gandhi and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Internal Medicine and Applied and Environmental Microbiology.

In The Last Decade

Matthew G. Johnson

34 papers receiving 934 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew G. Johnson United States	14	302	292	233	157	146	36	960
Rosemarie Metzger United States	14	73 0.2×	290 1.0×	318 1.4×	60 0.4×	79 0.5×	22	979
Ignacio Ayestarán Spain	17	52 0.2×	341 1.2×	116 0.5×	117 0.7×	127 0.9×	57	1.0k
Hans-Henrik Lervang Denmark	18	666 2.2×	410 1.4×	242 1.0×	86 0.5×	156 1.1×	29	1.3k
C. Venet France	13	73 0.2×	255 0.9×	76 0.3×	78 0.5×	43 0.3×	19	722
Vanessa Primeau Canada	6	320 1.1×	763 2.6×	303 1.3×	184 1.2×	629 4.3×	6	1.5k
Pilar Luqué Spain	13	86 0.3×	236 0.8×	93 0.4×	31 0.2×	113 0.8×	42	701
R Lang Israel	18	58 0.2×	223 0.8×	149 0.6×	113 0.7×	104 0.7×	37	841
M.J. Ricart Spain	23	71 0.2×	791 2.7×	514 2.2×	23 0.1×	298 2.0×	77	1.5k
Mario Antonini Italy	20	22 0.1×	280 1.0×	321 1.4×	128 0.8×	103 0.7×	59	987
Thilak Priyantha Weerarathna Sri Lanka	11	320 1.1×	221 0.8×	108 0.5×	41 0.3×	129 0.9×	38	788

Countries citing papers authored by Matthew G. Johnson

Since Specialization

Citations

This map shows the geographic impact of Matthew G. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew G. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew G. Johnson more than expected).

Fields of papers citing papers by Matthew G. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew G. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew G. Johnson. The network helps show where Matthew G. Johnson may publish in the future.

Co-authorship network of co-authors of Matthew G. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew G. Johnson. A scholar is included among the top collaborators of Matthew G. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew G. Johnson. Matthew G. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caraco, Yoseph, Matthew G. Johnson, Brian M. Maas, et al.. (2025). Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study. Clinical Trials. 22(3). 312–324.

Johnson, Matthew G., Julie Strizki, Erin Jensen, et al.. (2024). Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT). Microbiology Spectrum. 12(3). e0356323–e0356323.

Roilides, Emmanuel, et al.. (2023). Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis. Microbiology Spectrum. 11(5). e0180023–e0180023. 3 indexed citations

Puenpatom, Amy, Matthew G. Johnson, Ying Zhang, et al.. (2023). Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial. Clinical Infectious Diseases. 77(11). 1521–1530. 9 indexed citations

Virk, Abinash, Matthew G. Johnson, Daniel Roellinger, et al.. (2023). Hybrid Immunity Provides Protective Advantage Over Vaccination or Prior Remote Coronavirus Disease 2019 Alone. Open Forum Infectious Diseases. 10(5). ofad161–ofad161. 5 indexed citations

Johnson, Matthew G., Julie Strizki, Michelle Brown, et al.. (2023). Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. Infection. 51(5). 1273–1284. 23 indexed citations

Paterson, David L., Matteo Bassetti, Mary Motyl, et al.. (2022). Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial. Journal of Antimicrobial Chemotherapy. 77(9). 2522–2531. 15 indexed citations

Johnson, Matthew G., Christopher Bruno, Mariana Castanheira, et al.. (2021). Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP). International Journal of Antimicrobial Agents. 57(3). 106278–106278. 15 indexed citations

Lovely, Jenna K., et al.. (2020). Impact of a Program to Improve Venous Thromboembolism Prophylaxis on Incidence of Thromboembolism and Bleeding Rates in Hospitalized Patients During Implementation of Programs to Improve Venous Thromboembolism Prophylaxis. SHILAP Revista de lepidopterología. 4(2). 159–169. 6 indexed citations

10.

Ang, Jocelyn Y., Antonio Arrieta, John S. Bradley, et al.. (2020). Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population. American Journal of Perinatology. 38(8). 804–809. 13 indexed citations

11.

Carr, Donna, Zufei Zhang, Qian Si, et al.. (2020). In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant Pseudomonas Aeruginosa. Open Forum Infectious Diseases. 7(11). ofaa469–ofaa469. 3 indexed citations

12.

Bradley, John S., Jocelyn Y. Ang, Antonio Arrieta, et al.. (2018). Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. The Pediatric Infectious Disease Journal. 37(11). 1130–1136. 33 indexed citations

13.

Schneeweiß, Sebastian, Peggy L. Carver, Kausik Datta, et al.. (2016). Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. Journal of Antimicrobial Chemotherapy. 71(10). 2938–2944. 13 indexed citations

14.

Johnson, Matthew G. & Jason E. Stout. (2015). Twenty-eight cases of Mycobacterium marinum infection: retrospective case series and literature review. Infection. 43(6). 655–662. 92 indexed citations

15.

Johnson, Matthew G., et al.. (2013). Recognizing Laboratory Cross-Contamination. CHEST Journal. 144(1). 319–322. 7 indexed citations

16.

Borah, Bijan J., Michael G. Rock, Douglas L. Wood, et al.. (2012). Association between value-based purchasing score and hospital characteristics. BMC Health Services Research. 12(1). 464–464. 28 indexed citations

17.

Balon, Helena, Tracy L. Brown, Edward B. Silberstein, et al.. (2011). The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0. Journal of Nuclear Medicine Technology. 39(4). 317–324. 59 indexed citations

18.

Siddall, Mark E., et al.. (2006). Novel Role for Aeromonas jandaei as a Digestive Tract Symbiont of the North American Medicinal Leech. Applied and Environmental Microbiology. 73(2). 655–658. 16 indexed citations

19.

Patil, Arun Angelo, Richard Andrews, Matthew G. Johnson, & Jorge F. Rodriguez‐Sierra. (2004). Is Epilepsy Surgery on both Hemispheres Effective?. Stereotactic and Functional Neurosurgery. 82(5-6). 214–221. 12 indexed citations

20.

Immelman, E J, J. B. Bowes, A. C. Hunt, et al.. (1970). A Transportable Apparatus for Liver Preservation. European Surgical Research. 2(6). 427–434. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact